Lördag 21 December | 16:05:10 Europe / Stockholm

Kalender

Tid*
2025-02-27 12:00 Kvartalsrapport 2025-Q2
2024-12-09 - X-dag ordinarie utdelning ODI 0.00 SEK
2024-11-22 - Kvartalsrapport 2025-Q1
2024-11-19 - Extra Bolagsstämma 2024
2024-08-29 - Bokslutskommuniké 2024
2024-05-30 - Kvartalsrapport 2024-Q3
2024-02-22 - Kvartalsrapport 2024-Q2
2023-12-18 - X-dag ordinarie utdelning ODI 0.00 SEK
2023-12-15 - Årsstämma
2023-11-23 - Kvartalsrapport 2024-Q1
2023-08-24 - Bokslutskommuniké 2023
2023-05-25 - Kvartalsrapport 2023-Q3
2023-02-23 - Kvartalsrapport 2023-Q2
2022-12-16 - Årsstämma
2022-12-02 - X-dag ordinarie utdelning ODI 0.00 SEK
2022-11-24 - Kvartalsrapport 2023-Q1
2022-08-25 - Bokslutskommuniké 2022
2022-05-25 - Kvartalsrapport 2022-Q3
2022-02-24 - Kvartalsrapport 2022-Q2
2021-12-14 - X-dag ordinarie utdelning ODI 0.00 SEK
2021-12-13 - Årsstämma
2021-11-25 - Kvartalsrapport 2022-Q1
2021-08-26 - Bokslutskommuniké 2021
2021-05-27 - Kvartalsrapport 2021-Q3
2021-02-25 - Kvartalsrapport 2021-Q2
2020-12-28 - X-dag ordinarie utdelning ODI 0.00 SEK
2020-12-14 - Årsstämma
2020-11-27 - Kvartalsrapport 2021-Q1
2020-08-27 - Bokslutskommuniké 2020

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriLäkemedel & Handel
ODI Pharma är en producent samt leverantör av medicinska cannabisprodukter. Verksamheten drivs via dotterbolag och partners där försäljningen går via grossistdistributörer samt apotek. Produkterna används för behandling av exempelvis multipel skleros, kronisk smärta samt vid kemoterapi. Verksamhet återfinns inom den europeiska marknaden, med huvudkontoret i Stockholm.
2024-06-25 18:35:00

ODI Pharma AB ("ODI" or the "Company") is pleased to announce the first delivery of cannabis products to the leading medical cannabis provider in Switzerland. The delivery marks a symbolic milestone in ODI's market expansion efforts as it is the first delivery to the Swiss market. The delivery, which is facilitated through ODI's Swiss subsidiary, is less significant in terms of economic value but more important from a strategic point of view.

Exploration of Other European Markets

ODI Pharma is consolidating its position in the Eastern European medical cannabis market and is exploring additional European markets. This initiative is in line with ODI's goal to widen its market footprint and adapt to changing market dynamics. This order to the Swiss market, with products already shipped, represents a cautious yet forward-looking step towards a wider market engagement.
ODI's entry into Switzerland and other European markets signifies a commitment to strategic growth. By venturing into new territories, ODI aims to contribute to the evolving European medical cannabis landscape, leveraging its expertise to meet industry needs across the continent. This approach exemplifies ODI's optimism for the future, aiming to deliver value to patients and stakeholders while navigating the complexities of international markets.

For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
 

ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.